Article Text

PDF

Macrophage repolarisation therapy in colorectal cancer
  1. Niels Halama
  1. Department of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, UniversitatsKlinikum Heidelberg, Heidelberg, Germany
  1. Correspondence to Dr Niels Halama; niels.halama{at}nct-heidelberg.de

Abstract

Click here to listen to the Podcast

  • Podcast

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Although highly successful in other entities, immune checkpoint inhibition has so far only shown limited efficacy in an unselected population of patients with colorectal cancer. The particular composition of the inflammatory microenvironment of colorectal cancer, characterised by a low density of tumour infiltrating lymphocytes and no PDL1 expression on the tumour cells, might explain this resistance. Indeed, colorectal cancer with microsatellite instability responds much better to immune checkpoint inhibitors and presents with a much higher infiltration with T cells. Dense infiltration with tumour-associated macrophages at the invasion margin is a further characteristic of the inflammatory microenvironment in colorectal cancer, potentially causing the limited response to immune checkpoint inhibitors. Interestingly, PDL1 expression can be frequently observed on these tumour-associated macrophages at the invasion margin, which potentially reduce the infiltration with T cells. Interfering with this population of myeloid cells is a possible new immune modulating treatment approach, although more insight on the exact underlying mechanisms causing tumour supportive or suppressive behaviour of the myeloid cells is needed. Here, therapeutic approaches combining immune checkpoint inhibitor modulating the T cell function and specific modulators of the tumour-associated macrophages might be successful and should be investigated in future clinical trials.

View Abstract

Footnotes

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.